CO6781544A2 - Sal(es) de dimetil-amida del ácido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]-pirimidin-6-carboxílico y procesos para su elaboración. - Google Patents
Sal(es) de dimetil-amida del ácido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]-pirimidin-6-carboxílico y procesos para su elaboración.Info
- Publication number
- CO6781544A2 CO6781544A2 CO13115442A CO13115442A CO6781544A2 CO 6781544 A2 CO6781544 A2 CO 6781544A2 CO 13115442 A CO13115442 A CO 13115442A CO 13115442 A CO13115442 A CO 13115442A CO 6781544 A2 CO6781544 A2 CO 6781544A2
- Authority
- CO
- Colombia
- Prior art keywords
- piperazin
- pyrrolo
- elaboration
- pyrimidin
- pyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41206410P | 2010-11-10 | 2010-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6781544A2 true CO6781544A2 (es) | 2013-10-31 |
Family
ID=45094234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO13115442A CO6781544A2 (es) | 2010-11-10 | 2013-05-08 | Sal(es) de dimetil-amida del ácido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]-pirimidin-6-carboxílico y procesos para su elaboración. |
Country Status (24)
Country | Link |
---|---|
US (4) | US20120115878A1 (es) |
EP (2) | EP2638030B1 (es) |
JP (4) | JP2013542257A (es) |
KR (4) | KR20190099090A (es) |
CN (4) | CN113956257A (es) |
AR (2) | AR083797A1 (es) |
AU (4) | AU2011326620A1 (es) |
BR (2) | BR112013010167B1 (es) |
CA (1) | CA2815839C (es) |
CL (1) | CL2013001282A1 (es) |
CO (1) | CO6781544A2 (es) |
EC (1) | ECSP13012619A (es) |
ES (1) | ES2803432T3 (es) |
GT (1) | GT201300123A (es) |
IL (1) | IL225580B (es) |
JO (1) | JO3670B1 (es) |
MA (1) | MA34653B1 (es) |
MX (1) | MX370852B (es) |
MY (1) | MY164274A (es) |
PE (1) | PE20140065A1 (es) |
RU (1) | RU2631243C2 (es) |
SG (1) | SG189229A1 (es) |
TW (1) | TWI549953B (es) |
WO (1) | WO2012064805A1 (es) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
AR083797A1 (es) | 2010-11-10 | 2013-03-20 | Novartis Ag | Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos |
KR20140040770A (ko) | 2011-07-01 | 2014-04-03 | 노파르티스 아게 | 암 치료에 사용하기 위한 cdk4/6 억제제 및 pi3k 억제제를 포함하는 조합 요법 |
WO2014097125A1 (en) * | 2012-12-20 | 2014-06-26 | Novartis Ag | Pharmaceutical combination comprising binimetinib |
DK3149008T3 (en) * | 2014-05-28 | 2019-04-01 | Shanghai Fochon Pharmaceutical Co Ltd | Specific protein kinase inhibitors |
CN105294737B (zh) * | 2014-07-26 | 2019-02-12 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
WO2016077526A1 (en) | 2014-11-12 | 2016-05-19 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
CN105111215B (zh) * | 2014-12-12 | 2019-06-18 | 苏州晶云药物科技股份有限公司 | 一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法 |
US10138250B2 (en) | 2014-12-12 | 2018-11-27 | Crystal Pharmatech Co., Ltd. | Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt |
EP3231805B1 (en) * | 2014-12-12 | 2020-03-04 | Crystal Pharmatech Co. Ltd. | Salt of pyrrolo[2,3-d]pyrimidine compound and novel polymorph of salt |
JP2018509448A (ja) * | 2015-03-25 | 2018-04-05 | ノバルティス アーゲー | 組合せ医薬 |
US10323035B2 (en) | 2015-04-01 | 2019-06-18 | Crystal Pharmatech Co., Ltd. | Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof |
HRP20230053T1 (hr) | 2015-04-16 | 2023-03-03 | Novartis Ag | Tableta ribocikliba |
CN105037236B (zh) | 2015-06-04 | 2017-07-28 | 苏州明锐医药科技有限公司 | 瑞博西尼中间体及其制备方法 |
JP2018526376A (ja) * | 2015-08-28 | 2018-09-13 | ノバルティス アーゲー | がんの治療または予防のための(a)サイクリン依存性キナーゼ4/6(cdk4/6)阻害剤のlee011(=リボシクリブ)および(b)上皮成長因子受容体(egfr)阻害剤のエルロチニブを含む医薬組み合わせ物 |
EP3156406A1 (en) | 2015-10-14 | 2017-04-19 | ratiopharm GmbH | Crystalline forms of ribociclib free base |
CN116217729A (zh) | 2015-11-12 | 2023-06-06 | 思进公司 | 聚糖相互作用化合物及使用方法 |
CN106749259B (zh) * | 2015-11-19 | 2019-02-01 | 华东师范大学 | 一种环戊基嘧啶并吡咯类化合物的合成方法 |
CN107266451B (zh) * | 2016-04-07 | 2021-12-31 | 上海医药工业研究院 | 瑞布昔利布中间体的制备方法 |
ES2954148T3 (es) | 2016-05-07 | 2023-11-20 | Fochon Pharmaceuticals Ltd | Ciertos inhibidores de proteína cinasa |
CA3034875C (en) | 2016-08-23 | 2024-05-28 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
WO2018051280A1 (en) * | 2016-09-15 | 2018-03-22 | Dr. Reddy’S Laboratories Limited | Process for preparation of ribociclib, its acid addition salts |
AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
CN106478641B (zh) * | 2016-10-09 | 2018-07-24 | 杭州科巢生物科技有限公司 | 瑞博西尼中间体的合成方法 |
US11401330B2 (en) | 2016-11-17 | 2022-08-02 | Seagen Inc. | Glycan-interacting compounds and methods of use |
CN108314686A (zh) * | 2017-01-18 | 2018-07-24 | 西南民族大学 | 一种新颖的Ribociclib制备方法 |
JP2020510671A (ja) | 2017-03-03 | 2020-04-09 | シアトル ジェネティックス, インコーポレイテッド | グリカン相互作用化合物および使用の方法 |
AU2018234903B2 (en) | 2017-03-16 | 2024-02-08 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
CN108586356B (zh) * | 2017-03-16 | 2021-02-19 | 杭州科巢生物科技有限公司 | 瑞博西尼新中间体及其制备瑞博西尼的合成方法 |
CN108623599A (zh) * | 2017-03-17 | 2018-10-09 | 西南民族大学 | 一种快速合成Ribociclib方法 |
CN106928236B (zh) * | 2017-05-06 | 2019-05-31 | 山东君瑞医药科技有限公司 | 一种瑞博西尼的合成工艺 |
CN109206373B (zh) * | 2017-07-07 | 2022-02-15 | 上海医药工业研究院 | 一种帕博昔布中间体5-溴-2-氯-4-环戊基氨基嘧啶的制备工艺 |
WO2019019959A1 (zh) * | 2017-07-27 | 2019-01-31 | 苏州晶云药物科技股份有限公司 | 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途 |
SI3672968T1 (sl) | 2017-08-25 | 2024-03-29 | Assia Chemical Industries Ltd | Trdna oblika ribociklib sukcinata |
EP3676404A1 (en) | 2017-08-31 | 2020-07-08 | Novartis AG | Methods of selecting a treatment for cancer patients |
CN111164085B (zh) | 2017-09-29 | 2023-04-04 | 杭州领业医药科技有限公司 | 瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途 |
KR20200057705A (ko) | 2017-10-27 | 2020-05-26 | 프레세니어스 카비 온콜로지 리미티드 | 리보시클립 및 그의 염의 제조를 위한 개선된 방법 |
WO2019111160A1 (en) * | 2017-12-04 | 2019-06-13 | Sun Pharmaceutical Industries Limited | Crystalline forms of ribociclib succinate |
US11111250B2 (en) | 2017-12-22 | 2021-09-07 | Shilpa Meicare Limited | Polymorphs of Ribociclib mono succinate |
IN201741000072A (es) * | 2017-12-29 | 2018-07-06 | ||
CN107936029B (zh) * | 2018-01-08 | 2020-06-30 | 南京奇可药业有限公司 | 一种合成瑞博西尼的方法 |
CN110016024B (zh) * | 2018-01-09 | 2021-09-03 | 南京药石科技股份有限公司 | 一种合成cdk4/6双重抑制剂的关键中间体及其制备方法和应用 |
WO2019142206A1 (en) * | 2018-01-20 | 2019-07-25 | Natco Pharma Limited | An improved process for the preparation of ribociclib succinate and its novel crystalline forms thereof |
WO2019150181A1 (en) * | 2018-02-05 | 2019-08-08 | Biophore India Pharmaceuticals Pvt Ltd | Improved process for the preparation of 7-cyclopentyl-n, n-dimethyl-2-(5-(piperazin-1-yl) pyridin-2-ylaminuteso)-7h-pyrrolo[2,3-d] pyrimidine-6-carboxamide succinate (ribociclib succinate) and its crystalline forms thereof |
WO2019166987A1 (en) * | 2018-02-28 | 2019-09-06 | Sun Pharmaceutical Industries Limited | A process for the preparation of ribociclib and its intermediates |
WO2019167068A1 (en) | 2018-03-01 | 2019-09-06 | Cipla Limited | Novel polymorphs of ribociclib succinate |
US10723739B2 (en) | 2018-05-14 | 2020-07-28 | Apotex Inc. | Processes for the preparation of Ribociclib and intermediates thereof |
TWI675662B (zh) | 2018-05-17 | 2019-11-01 | 中化合成生技股份有限公司 | 瑞博西尼琥珀酸鹽(Ribociclib succinate salt)晶型B、C及D與其衍生物,以及其等之製造方法與藥物組合物 |
CA3048036A1 (en) | 2018-07-02 | 2020-01-02 | Apotex Inc | Novel crystalline form of ribociclib succinate |
CN110156793B (zh) * | 2018-07-13 | 2022-01-14 | 安礼特(上海)医药科技有限公司 | 瑞博西尼单琥珀酸盐新晶型及制备方法 |
WO2020084389A1 (en) | 2018-10-23 | 2020-04-30 | Lupin Limited | Ribociclib intermediate and process for preparation thereof |
CN111100128B (zh) * | 2018-10-26 | 2022-09-06 | 广安凯特制药有限公司 | 一种瑞博西尼中间产品的合成方法及其中间体化合物 |
TW202038957A (zh) | 2018-12-21 | 2020-11-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與激酶抑制劑之組合 |
CN109400612A (zh) * | 2018-12-24 | 2019-03-01 | 重庆三圣实业股份有限公司 | 一种瑞博西尼的制备方法及其产品和用途 |
EP3914353A1 (en) | 2019-01-23 | 2021-12-01 | Novartis AG | New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide |
WO2020225827A1 (en) | 2019-05-08 | 2020-11-12 | Mylan Laboratories Limited | Novel polymorphs of ribociclib succinate |
CN112010857B (zh) * | 2019-05-30 | 2021-11-05 | 常州制药厂有限公司 | 一种瑞博西尼单丁二酸盐的晶型 |
WO2021038590A1 (en) | 2019-08-30 | 2021-03-04 | Mylan Laboratories Limited | Novel polymorph of ribociclib succinate |
WO2021229439A1 (en) | 2020-05-12 | 2021-11-18 | Novartis Ag | Therapeutic combinations comprising a craf inhibitor |
EP4313987A2 (en) | 2021-04-01 | 2024-02-07 | KRKA, d.d., Novo mesto | Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof |
CN113636973B (zh) * | 2021-09-07 | 2023-04-07 | 山东铂源药业股份有限公司 | 一种4-(6-氨基吡啶-3-基)哌嗪-1-羧酸叔丁酯的工业化制备方法 |
WO2023107525A1 (en) | 2021-12-10 | 2023-06-15 | Eli Lilly And Company | Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor |
WO2023114264A1 (en) | 2021-12-15 | 2023-06-22 | Eli Lilly And Company | Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer |
TW202329977A (zh) | 2022-01-25 | 2023-08-01 | 瑞士商諾華公司 | 瑞博西尼藥物組成物 |
WO2024049926A1 (en) | 2022-08-31 | 2024-03-07 | Arvinas Operations, Inc. | Dosage regimens of estrogen receptor degraders |
JP2024067010A (ja) | 2022-11-02 | 2024-05-16 | ペトラ・ファーマ・コーポレイション | 疾患の治療用のホスホイノシチド3-キナーゼ(pi3k)のアロステリッククロメノン阻害剤 |
WO2024115680A1 (en) | 2022-12-01 | 2024-06-06 | Krka, D.D., Novo Mesto | Ribociclib salts and formulations thereof |
CN117069663B (zh) * | 2023-08-31 | 2023-12-26 | 四川维亚本苑生物科技有限公司 | 一种瑞博西尼中间体v的合成方法及瑞博西尼的合成方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI992711A1 (it) | 1999-12-27 | 2001-06-27 | Novartis Ag | Composti organici |
ATE468339T1 (de) * | 2001-12-20 | 2010-06-15 | Osi Pharm Inc | Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung |
CN102060806A (zh) | 2003-09-11 | 2011-05-18 | iTherX药品公司 | 细胞因子抑制剂 |
JP4989233B2 (ja) * | 2004-02-14 | 2012-08-01 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
EP1781647A2 (en) | 2004-07-22 | 2007-05-09 | Astex Therapeutics Limited | Thiazole and isothiazole derivatives as protein kinase inhibitors |
WO2006091737A1 (en) * | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
EP1910218A1 (en) | 2005-07-22 | 2008-04-16 | Qualcomm Mems Technologies, Inc. | Mems devices having support structures and methods of fabricating the same |
CN101356159A (zh) * | 2005-12-22 | 2009-01-28 | 惠氏公司 | 经取代异喹啉-1,3(2h,4h)-二酮类、1-硫代-1,4-二氢-2h-异喹啉-3-酮类和1,4-二氢-3(2h)-异喹啉酮类以及其作为激酶抑制剂的用途 |
JO3235B1 (ar) * | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
KR101353857B1 (ko) * | 2008-08-22 | 2014-01-21 | 노파르티스 아게 | Cdk 억제제로서 피롤로피리미딘 화합물 |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
AR083797A1 (es) * | 2010-11-10 | 2013-03-20 | Novartis Ag | Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos |
-
2011
- 2011-11-08 AR ARP110104165A patent/AR083797A1/es active IP Right Grant
- 2011-11-08 US US13/291,187 patent/US20120115878A1/en not_active Abandoned
- 2011-11-09 AU AU2011326620A patent/AU2011326620A1/en not_active Abandoned
- 2011-11-09 CN CN202110832802.9A patent/CN113956257A/zh active Pending
- 2011-11-09 CA CA2815839A patent/CA2815839C/en active Active
- 2011-11-09 MX MX2013005292A patent/MX370852B/es active IP Right Grant
- 2011-11-09 KR KR1020197023852A patent/KR20190099090A/ko not_active Application Discontinuation
- 2011-11-09 BR BR112013010167-9A patent/BR112013010167B1/pt active IP Right Grant
- 2011-11-09 CN CN2011800541083A patent/CN103201275A/zh not_active Withdrawn
- 2011-11-09 KR KR1020137011989A patent/KR20130132433A/ko active Application Filing
- 2011-11-09 US US13/882,353 patent/US9193732B2/en active Active
- 2011-11-09 PE PE2013000978A patent/PE20140065A1/es not_active Application Discontinuation
- 2011-11-09 BR BR122021022703-9A patent/BR122021022703B1/pt active IP Right Grant
- 2011-11-09 JP JP2013538838A patent/JP2013542257A/ja active Pending
- 2011-11-09 KR KR1020187027991A patent/KR20180112079A/ko active Search and Examination
- 2011-11-09 SG SG2013024534A patent/SG189229A1/en unknown
- 2011-11-09 EP EP11791110.7A patent/EP2638030B1/en active Active
- 2011-11-09 WO PCT/US2011/059890 patent/WO2012064805A1/en active Application Filing
- 2011-11-09 TW TW100140959A patent/TWI549953B/zh active
- 2011-11-09 CN CN201510746374.2A patent/CN105399743A/zh active Pending
- 2011-11-09 MY MYPI2013001156A patent/MY164274A/en unknown
- 2011-11-09 RU RU2013126112A patent/RU2631243C2/ru active
- 2011-11-09 ES ES11791110T patent/ES2803432T3/es active Active
- 2011-11-09 CN CN201510746385.0A patent/CN105384741B/zh active Active
- 2011-11-09 KR KR1020207033901A patent/KR20200136493A/ko not_active Application Discontinuation
- 2011-11-09 EP EP20168336.4A patent/EP3753933A1/en not_active Withdrawn
- 2011-11-12 JO JOP/2011/0332A patent/JO3670B1/ar active
-
2013
- 2013-04-04 IL IL225580A patent/IL225580B/en active IP Right Grant
- 2013-05-07 MA MA35884A patent/MA34653B1/fr unknown
- 2013-05-08 CO CO13115442A patent/CO6781544A2/es not_active Application Discontinuation
- 2013-05-09 CL CL2013001282A patent/CL2013001282A1/es unknown
- 2013-05-10 EC ECSP13012619 patent/ECSP13012619A/es unknown
- 2013-05-10 GT GT201300123A patent/GT201300123A/es unknown
-
2014
- 2014-06-18 US US14/307,901 patent/US20150099760A1/en not_active Abandoned
-
2015
- 2015-10-20 US US14/887,790 patent/US9868739B2/en active Active
-
2016
- 2016-05-27 AU AU2016203534A patent/AU2016203534B2/en active Active
- 2016-10-14 JP JP2016202167A patent/JP6534375B2/ja active Active
- 2016-10-14 JP JP2016202168A patent/JP2017039757A/ja not_active Withdrawn
-
2017
- 2017-08-30 AU AU2017221805A patent/AU2017221805A1/en not_active Abandoned
-
2018
- 2018-09-28 JP JP2018184166A patent/JP2019038809A/ja active Pending
- 2018-12-04 AU AU2018274883A patent/AU2018274883B2/en active Active
-
2020
- 2020-01-10 AR ARP200100071A patent/AR117799A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6781544A2 (es) | Sal(es) de dimetil-amida del ácido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]-pirimidin-6-carboxílico y procesos para su elaboración. | |
HRP20190145T1 (hr) | Neuronavigacijski vođeni fokusirani ultrazvučni sustav | |
CL2016001080A1 (es) | Benzamidas sustituidas para tratamiento de artrópodos. | |
BR112015011903A2 (pt) | dispositivo de rastreamento. | |
BR112014027478A2 (pt) | métodos de processamento de materiais lingnocelulósicos". | |
BR112015001201A2 (pt) | compostos anti-infecciosos 5,5-heteroaromáticos. | |
BR112015003320A2 (pt) | aparelhos e métodos eletrocirúrgicos. | |
BR112015002958A2 (pt) | aparelho de posicionamento de paciente articulado. | |
JP2011170856A5 (es) | ||
BR112015002960A2 (pt) | aparelho de gravação. | |
BR112014028916A2 (pt) | dispositivo urológico implantável com recurso de recuperação. | |
ITRM20130667A1 (it) | Impianto di alimentzione di caburante. | |
BR112014028871A2 (pt) | linhagens de propionibacterium. | |
BR112014030159A2 (pt) | agente para tratamento de floculação. | |
FR2968601B1 (fr) | Pneumatique ayant des bourrelets perfectionnes. | |
BR112014028380A2 (pt) | sistema de entrada". | |
DK2816947T3 (da) | Endoskopisk anordning, særlig til medicinsk brug | |
BRPI1008706A2 (pt) | dispositivo para diagnóstico. | |
FR2995869B1 (fr) | Véhicule inclinable. | |
FR2983123B1 (fr) | Pneumatique ayant des bourrelets perfectionnes. | |
BR112014028678A2 (pt) | sistema de rfid com acoplamento ca. | |
GB201220835D0 (en) | S/V.D.R.-;system | |
BR112014029090A2 (pt) | mangueira marítima de dupla carcaça. | |
BR112015000134A2 (pt) | formulação de herbicida. | |
FR3005864B1 (fr) | Procede de decontamination. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |